文献速递妇科

上皮性卵巢癌与循环肿瘤DNA应用的系统综述

Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
PubMed 文献 · Gynecol Oncol · 2021-04-21

该系统综述纳入36项观察性研究,评估血浆或血清循环肿瘤DNA(ctDNA)在上皮性卵巢癌(EOC)中的应用。ctDNA分析方法和样本量差异大,但总体显示ctDNA在诊断、治疗反应监测和预后方面是有前景的生物标志物,尚需更多研究确立理想方法和应用场景。

要点

  • ctDNA在EOC诊断、治疗反应监测和预后方面显示潜在价值。
  • 纳入研究ctDNA分析方法差异大,样本量仅10-126例。
  • 尚无研究评估ctDNA用于复发早期检测。

核心结论

  • ctDNA作为EOC生物标志物在诊断、治疗反应监测和预后方面有前景。
  • 需更多研究确立ctDNA在EOC临床应用的理想方法和场景。

研究设计与样本

  • 系统综述,检索Pubmed、Embase和Scopus,遵循PRISMA指南。
  • 共纳入36项观察性研究,样本量10-126例患者。

主要发现

  • 19项研究评估肿瘤与ctDNA一致性,23项评估诊断,7项监测治疗反应,9项评估预后,3项检测逆转突变,1项评估早期诊断。
  • 无研究评估ctDNA用于复发早期检测。
  • 研究间ctDNA分析方法差异大,数据为描述性报告。

临床怎么用

  • ctDNA可作为EOC诊断、治疗反应监测和预后评估的潜在生物标志物。
  • 临床使用前需注意现有研究方法差异大且样本量有限。

局限性

  • 纳入研究数量有限且ctDNA分析方法差异大。
  • 研究样本量较小(10-126例)。
  • 无研究评估ctDNA对复发早期检测的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: One way to improve the survival rate of epithelial Ovarian Cancer (EOC) is by identifying effective biomarkers useful at different stages and time points of the disease. A potential biomarker is circulating tumor DNA (ctDNA) in plasma or serum. In this systematic review, we provide an overview of applications of ctDNA in EOC to discuss the direction of future research in this field. METHODS: We performed a systematic search in Pubmed, Embase, and Scopus to identify relevant clinical studies eligible for inclusion. Furthermore, the references in the identified studies and relevant reviews were assessed to identify additional studies. The PRISMA guideline was employed to perform the systematic review, and data from the studies were extracted using piloted data extraction forms. RESULTS: A total of 36 observational studies were included. The concordance between tumor and ctDNA was assessed in 19 studies, early diagnosis in 1, diagnosis in 23, monitoring of treatment response in 7, detection of reversion mutations in 3, prognosis in 9, but no studies assessed early detection of recurrence. Data from the studies were reported descriptively. The studies had a large variation in the methods used for ctDNA analysis and limited sample sizes of 10-126 patients. Overall, the studies show that ctDNA is a potential biomarker for EOC useful in several settings during assessment and treatment of these patients. CONCLUSIONS: Although the identified studies are limited in number and their methods for ctDNA analysis vary, it is clear that ctDNA as a biomarker for EOC is promising for several applications in diagnostics, monitoring of treatment response, and prognostics. However, more studies are needed to establish the ideal methods and settings for the clinical use of ctDNA in EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Thusgaard CF, Korsholm M, Koldby KM, et al. Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review. Gynecol Oncol. 2021. PMID: 33892886. doi:10.1016/j.ygyno.2021.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。